UF Innovate | Sid Martin Biotech alum AxoGen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License Application (BLA) submission for Avance Nerve Graft has reached its enrollment target of 220 subjects. RECON … Continue reading Axogen Recon Clinical Study Completes Target Enrollment of 220 Subjects